Teleflex (TFX)
Market Price (4/7/2026): $114.12 | Market Cap: $5.0 BilSector: Health Care | Industry: Health Care Equipment
Teleflex (TFX)
Market Price (4/7/2026): $114.12Market Cap: $5.0 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12% Low stock price volatilityVol 12M is 39% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Medical Device Innovation. Themes include Geriatric Care, Minimally Invasive Surgical Solutions, Show more. | Weak multi-year price returns2Y Excs Rtn is -73%, 3Y Excs Rtn is -116% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 41x Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -7.4% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% Key risksTFX key risks include [1] heightened operational and execution challenges from the simultaneous acquisition of BIOTRONIK's vascular business and the planned spin-off of three other divisions, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12% |
| Low stock price volatilityVol 12M is 39% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Medical Device Innovation. Themes include Geriatric Care, Minimally Invasive Surgical Solutions, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -73%, 3Y Excs Rtn is -116% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 41x |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -7.4% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% |
| Key risksTFX key risks include [1] heightened operational and execution challenges from the simultaneous acquisition of BIOTRONIK's vascular business and the planned spin-off of three other divisions, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Teleflex (TFX) stock has lost about 5% since 12/31/2025 because of the following key factors:
1. Teleflex reported a significant miss on its Fourth Quarter 2025 earnings and revenue, alongside lower-than-expected 2026 guidance. The company announced Q4 2025 earnings on February 26, 2026, with an adjusted EPS of $1.93, missing analysts' consensus estimates of approximately $3.73 by $1.80. Quarterly revenue also declined 28.5% year-over-year to $569 million, falling short of the consensus estimate of over $912 million. Furthermore, Teleflex issued adjusted EPS guidance for the full year 2026 in the range of $6.25 to $6.55, which was substantially lower than the previous consensus estimate of $15.18.
2. Strategic divestitures and associated "stranded costs" negatively impacted the near-term financial outlook. Teleflex announced the divestiture of its Acute Care, Interventional Urology, and OEM businesses, expected to generate approximately $1.8 billion in net after-tax proceeds. While these divestitures aim to streamline the portfolio, they introduced an estimated $90 million in "stranded costs" for 2026, directly contributing to the reduced adjusted EPS guidance.
Show more
1. Teleflex reported a significant miss on its Fourth Quarter 2025 earnings and revenue, alongside lower-than-expected 2026 guidance. The company announced Q4 2025 earnings on February 26, 2026, with an adjusted EPS of $1.93, missing analysts' consensus estimates of approximately $3.73 by $1.80. Quarterly revenue also declined 28.5% year-over-year to $569 million, falling short of the consensus estimate of over $912 million. Furthermore, Teleflex issued adjusted EPS guidance for the full year 2026 in the range of $6.25 to $6.55, which was substantially lower than the previous consensus estimate of $15.18.
2. Strategic divestitures and associated "stranded costs" negatively impacted the near-term financial outlook. Teleflex announced the divestiture of its Acute Care, Interventional Urology, and OEM businesses, expected to generate approximately $1.8 billion in net after-tax proceeds. While these divestitures aim to streamline the portfolio, they introduced an estimated $90 million in "stranded costs" for 2026, directly contributing to the reduced adjusted EPS guidance.
Show more
Stock Movement Drivers
Fundamental Drivers
The -5.5% change in TFX stock from 12/31/2025 to 4/6/2026 was primarily driven by a -12.6% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 4062026 | Change |
|---|---|---|---|
| Stock Price ($) | 121.69 | 115.04 | -5.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,842 | 1,993 | 8.2% |
| P/S Multiple | 2.9 | 2.6 | -12.6% |
| Shares Outstanding (Mil) | 44 | 44 | 0.0% |
| Cumulative Contribution | -5.5% |
Market Drivers
12/31/2025 to 4/6/2026| Return | Correlation | |
|---|---|---|
| TFX | -5.5% | |
| Market (SPY) | -5.4% | 27.4% |
| Sector (XLV) | -5.5% | 29.3% |
Fundamental Drivers
The -5.4% change in TFX stock from 9/30/2025 to 4/6/2026 was primarily driven by a -19.7% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 4062026 | Change |
|---|---|---|---|
| Stock Price ($) | 121.63 | 115.04 | -5.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,694 | 1,993 | 17.7% |
| P/S Multiple | 3.2 | 2.6 | -19.7% |
| Shares Outstanding (Mil) | 44 | 44 | 0.1% |
| Cumulative Contribution | -5.4% |
Market Drivers
9/30/2025 to 4/6/2026| Return | Correlation | |
|---|---|---|
| TFX | -5.4% | |
| Market (SPY) | -2.9% | 28.8% |
| Sector (XLV) | 5.6% | 28.2% |
Fundamental Drivers
The -15.8% change in TFX stock from 3/31/2025 to 4/6/2026 was primarily driven by a -31.5% change in the company's P/S Multiple.| (LTM values as of) | 3312025 | 4062026 | Change |
|---|---|---|---|
| Stock Price ($) | 136.61 | 115.04 | -15.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,700 | 1,993 | 17.2% |
| P/S Multiple | 3.7 | 2.6 | -31.5% |
| Shares Outstanding (Mil) | 46 | 44 | 4.8% |
| Cumulative Contribution | -15.8% |
Market Drivers
3/31/2025 to 4/6/2026| Return | Correlation | |
|---|---|---|
| TFX | -15.8% | |
| Market (SPY) | 16.3% | 38.5% |
| Sector (XLV) | 1.6% | 43.1% |
Fundamental Drivers
The -53.4% change in TFX stock from 3/31/2023 to 4/6/2026 was primarily driven by a -38.5% change in the company's P/S Multiple.| (LTM values as of) | 3312023 | 4062026 | Change |
|---|---|---|---|
| Stock Price ($) | 247.08 | 115.04 | -53.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,791 | 1,993 | -28.6% |
| P/S Multiple | 4.2 | 2.6 | -38.5% |
| Shares Outstanding (Mil) | 47 | 44 | 6.1% |
| Cumulative Contribution | -53.4% |
Market Drivers
3/31/2023 to 4/6/2026| Return | Correlation | |
|---|---|---|
| TFX | -53.4% | |
| Market (SPY) | 63.3% | 34.7% |
| Sector (XLV) | 18.3% | 42.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| TFX Return | -20% | -24% | 0% | -28% | -31% | -3% | -70% |
| Peers Return | 12% | -12% | 12% | 14% | 6% | -10% | 20% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -4% | 75% |
Monthly Win Rates [3] | |||||||
| TFX Win Rate | 33% | 50% | 50% | 50% | 50% | 25% | |
| Peers Win Rate | 55% | 48% | 55% | 62% | 57% | 45% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| TFX Max Drawdown | -29% | -43% | -28% | -30% | -41% | -18% | |
| Peers Max Drawdown | -9% | -26% | -8% | -8% | -8% | -13% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, BDX, BSX, EW, SYK. See TFX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/6/2026 (YTD)
How Low Can It Go
| Event | TFX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -59.6% | -25.4% |
| % Gain to Breakeven | 147.4% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -43.0% | -33.9% |
| % Gain to Breakeven | 75.4% | 51.3% |
| Time to Breakeven | 128 days | 148 days |
| 2018 Correction | ||
| % Loss | -20.7% | -19.8% |
| % Gain to Breakeven | 26.1% | 24.7% |
| Time to Breakeven | 199 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -55.7% | -56.8% |
| % Gain to Breakeven | 125.9% | 131.3% |
| Time to Breakeven | 1,463 days | 1,480 days |
Compare to MDT, BDX, BSX, EW, SYK
In The Past
Teleflex's stock fell -59.6% during the 2022 Inflation Shock from a high on 4/28/2021. A -59.6% loss requires a 147.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Teleflex (TFX)
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
AI Analysis | Feedback
Teleflex is like the Medtronic or Johnson & Johnson (medical device segment) of single-use medical devices, supplying a vast array of essential tools for critical care and surgery.
Alternatively, think of them as similar to Stryker or Boston Scientific, but with a broader portfolio of everyday, single-use medical tools and supplies for hospital procedures, from vascular access to urology.
AI Analysis | Feedback
- Vascular Access Products: Catheters and related systems for administering intravenous therapies, measuring blood pressure, and withdrawing blood samples.
- Interventional Products: Specialized catheters and devices used by interventional cardiologists, radiologists, and vascular surgeons for various procedures, including structural heart and peripheral interventions.
- Anesthesia Products: Airway and pain management products supporting critical care, emergency medicine, and surgical applications.
- Surgical Products: Metal and polymer ligation clips, fascial closure surgical systems, and other instruments for laparoscopic and other surgical procedures.
- Interventional Urology Products: The UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia.
- Respiratory Products: Devices for oxygen and aerosol therapies, spirometry, and ventilation management.
- Urology Products: Catheters, urine collectors, and accessories for bladder management and operative endourology.
AI Analysis | Feedback
Teleflex (TFX) sells primarily to other organizations and companies. Its major customers fall into the following categories:
- Hospitals and healthcare providers
- Medical device manufacturers
- Home care markets
AI Analysis | Feedback
null
AI Analysis | Feedback
Stuart Randle, Interim President and Chief Executive Officer
Stuart Randle was appointed Interim President and Chief Executive Officer of Teleflex on January 8, 2026. He has been a member of the Teleflex Board of Directors since 2009. Mr. Randle brings over 35 years of experience in the medical device industry. Prior to his current role, he served as Chief Executive Officer of Ivenix, Inc. for three years and as President and Chief Executive Officer of GI Dynamics, Inc. for ten years. His previous leadership experience also includes serving as Interim Chief Executive Officer of Optobionics Corporation from 2003 to 2004 and President and Chief Executive Officer of Act Medical from 1998 to 2001. He also held various senior management positions with Allegiance Healthcare Corporation and Baxter International Inc.
John R. Deren, Executive Vice President and Chief Financial Officer
John R. Deren is the Executive Vice President and Chief Financial Officer of Teleflex, a role he assumed on April 2, 2025. He joined Teleflex in 2013 and possesses over 30 years of experience in financial management and reporting. Mr. Deren's prior experience includes leadership positions at Rohm and Haas, Exelon Generation, and Trinseo. He started his career as a Certified Public Accountant (CPA) at PricewaterhouseCoopers.
Jay White, Corporate Vice President and President, Global Commercial
Jay White serves as Corporate Vice President and President, Global Commercial at Teleflex. He joined Teleflex in March 2005 as Director of Marketing, North America. He was promoted to President and General Manager of the Surgical business in January 2013, and subsequently became President and General Manager of the Vascular business in December 2013. In February 2017, he was named President, The Americas. Before joining Teleflex, Mr. White held senior leadership positions in sales and marketing at Covidien (now part of Medtronic plc) for five years. He holds a Bachelor of Science degree from the University of Missouri.
Daniel V. Logue, Corporate Vice President, General Counsel and Secretary
Daniel V. Logue is the Corporate Vice President, General Counsel and Secretary of Teleflex. He joined Teleflex in September 2015 as Vice President and Chief Compliance Officer. In February 2016, he assumed the role of Vice President, General Counsel, and Chief Compliance Officer, and was appointed Corporate Vice President in February 2017. Prior to joining Teleflex, Mr. Logue served as Vice President and Associate General Counsel for Allergan plc. He also held various legal leadership roles at Actavis plc and Pfizer Inc. He began his legal career in private practice at Drinker Biddle & Reath LLP. Mr. Logue holds a Juris Doctor from Temple University School of Law and a Bachelor of Arts from Villanova University.
Cameron Hicks, Corporate Vice President and Chief Human Resources Officer
Cameron Hicks is the Corporate Vice President and Chief Human Resources Officer at Teleflex. He joined Teleflex in April 2013, bringing over 23 years of experience in Human Resources and Organizational Development to his role. Prior to joining Teleflex, Mr. Hicks held various human resources leadership positions at other companies. He earned a Bachelor of Arts degree from the University of California, Santa Barbara.
AI Analysis | Feedback
The key risks to Teleflex's business include:- Regulatory Hurdles and Product Recalls: Teleflex operates in a highly regulated industry, facing stringent requirements from bodies such as the U.S. Food and Drug Administration (FDA) and the European Union Medical Device Regulation (EU MDR). The process of obtaining and maintaining regulatory approvals can be lengthy, uncertain, and costly, including the re-registration of previously approved devices under new regulations. A significant risk also stems from product recalls due to manufacturing errors, which can lead to serious injuries or even death. For example, Teleflex has initiated Class I recalls for intra-aortic balloon catheter kits and peripheral catheter systems due to issues like overtwisted balloons or catheter separation, with reported injuries and deaths. Such recalls can result in significant legal and financial consequences, as well as damage to the company's reputation.
- Intense Competition and Pricing Pressure: Teleflex faces significant competition from both large, diversified medical device companies (such as Medtronic, Boston Scientific, and Edwards Lifesciences) and specialized niche players across its various product segments. This competitive landscape can lead to pricing pressure, particularly in commoditized product lines, and challenges in maintaining or expanding market share. Competitors often leverage broad portfolios and distribution networks, putting pressure on Teleflex's market position in areas like vascular access and anesthesia.
- Product-Specific Challenges and Demand Softness: Certain key product lines have experienced specific challenges. The UroLift System, an important interventional urology product, has faced headwinds due to changes in reimbursement policies. Additionally, Teleflex has seen softer demand for intra-aortic balloon pumps and catheters, as well as delays in OEM orders, which has led to trimmed revenue guidance. Overall, the company has observed declining long-term sales and constant currency revenue growth that has lagged the broader sector, suggesting underlying demand headwinds that could impact future profitability.
AI Analysis | Feedback
nullAI Analysis | Feedback
Teleflex, trading under the symbol TFX, operates in several significant medical device markets globally. The addressable markets for its main products and services are sized as follows:Addressable Markets for Teleflex Products and Services
- Interventional Cardiology Devices: The global interventional cardiology devices market was estimated at approximately USD 20.9 billion in 2025 and is projected to reach USD 46.8 billion by 2035. North America is a dominant region in this market, holding an estimated 44.91% share in 2025.
- Structural Heart Devices: The global structural heart devices market was valued at USD 12.3 billion in 2024 and is expected to reach USD 28.8 billion by 2034. Another report indicated a market size of USD 14.65 billion in 2025, projected to grow to USD 27.16 billion by 2034. North America held the largest revenue share in 2024, accounting for 52.5% of the global market. The U.S. structural heart devices market was valued at USD 3.8 billion in 2024.
- Anesthesia and Respiratory Devices: The global anesthesia and respiratory devices market was estimated at USD 56.12 billion in 2025 and is expected to reach USD 84.50 billion by 2032. North America is expected to hold a 42.3% share of this global market in 2025. Specifically, the U.S. anesthesia and respiratory devices market was valued at USD 9.24 billion in 2024 and is projected to reach approximately USD 17.44 billion by 2034.
- Surgical Instruments/Equipment: The global surgical equipment market was estimated at USD 20.75 billion in 2024 and is poised to grow to USD 48.14 billion by 2033. North America dominated the global market in 2024, holding a 38.2% share. The U.S. surgical instruments market is estimated to reach US$12.1 billion by 2031. The global minimally invasive surgical instruments market was valued at US$29.9 billion in 2023 and is projected to reach US$49.9 billion by 2029. The U.S. minimally invasive surgical instrument market was valued at USD 11.6 billion in 2025.
- Benign Prostatic Hyperplasia (BPH) Treatment Devices (including UroLift System): The global benign prostatic hyperplasia (BPH) treatment device market size was estimated at USD 1.67 billion in 2024 and is projected to reach USD 3.71 billion by 2033. Another report indicated the global market was valued at USD 4.9 billion in 2024, expected to reach USD 7.3 billion by 2030. North America dominated the BPH treatment device market with the largest revenue share of 33.87% in 2024.
- Respiratory Care Devices: The global respiratory care devices market size was valued at USD 25.33 billion in 2024 and is projected to grow to USD 39.24 billion by 2032. North America dominated this market with a 40.43% share in 2024, with the U.S. holding about 45% of the global market share.
- Urology Devices: The global urology devices market size was estimated at USD 36.8 billion in 2024 and is expected to grow to USD 73.5 billion in 2034. North America dominated the global urology devices market with the highest market share of 42.5% in 2024. The U.S. urology devices market was valued at USD 14.4 billion in 2024.
AI Analysis | Feedback
Teleflex (TFX) is expected to drive future revenue growth over the next two to three years through several key strategies focused on its core "RemainCo" operations, which include Vascular Access, Interventional, and Surgical businesses. Here are the expected drivers of future revenue growth:- Expansion of the Interventional Segment with strategic acquisitions and key products: The Interventional segment is projected to be a primary engine of growth, with expectations for a high-single-digit expansion rate. A significant contributor to this growth is the acquired BIOTRONIK Vascular Intervention business, which is anticipated to achieve constant currency revenue growth of 6% or more starting in 2026. This acquisition enhances Teleflex's offerings in the interventional cardiology and peripheral intervention markets, including a broad suite of devices such as drug-coated balloons and stents. Additionally, the MANTA Vascular Closure Device is expected to contribute to revenue growth, particularly in large-bore closure procedures like TAVR, leveraging its proven efficacy and growing adoption in international markets.
- Increased Investment in Research and Development (R&D) and Product Innovation: Teleflex plans to increase its R&D spending for its continuing operations to approximately 8% of sales, a notable increase from its historical 5% company-wide allocation. This elevated investment is strategically directed towards fostering procedural simplicity, integrating AI augmentation, and launching new products within its core Vascular Access, Interventional, and Surgical segments. This focus on innovation aims to address unmet clinical needs and differentiate its product portfolio, thereby stimulating demand and revenue growth.
- Targeted Geographic Expansion and Market Penetration: The company is focused on expanding its global footprint and increasing market penetration, particularly in emerging markets and key regions such as EMEA (Europe, Middle East, and Africa) and Asia. This strategy involves localized product portfolios and leveraging targeted sales channels and distributor partnerships to capitalize on growth opportunities in these regions for its Vascular Access, Interventional, and Surgical product lines. For instance, analysts anticipate significant year-over-year growth in geographic revenues for both EMEA and Asia.
- Realization of Operational Efficiencies and Margin Expansion through Restructuring: Teleflex has initiated a multi-year restructuring plan designed to achieve approximately $50 million in annual pre-tax savings by mid-2028. These cost structure initiatives, coupled with a favorable sales mix towards higher-margin products, are projected to enhance the adjusted operating margin. While primarily impacting profitability, improved efficiencies and margin expansion can indirectly support revenue growth by allowing for more competitive pricing strategies or by freeing up capital for further investments in product development and market expansion.
AI Analysis | Feedback
Share Repurchases
- Teleflex authorized a $500 million share repurchase program in July 2024, initiating a $200 million accelerated share repurchase in August 2024.
- The company intended to commence an additional $300 million accelerated share repurchase in February 2025 under the existing $500 million authorization.
- In December 2025, Teleflex authorized a new $1 billion share repurchase program, primarily to be funded by proceeds from upcoming business divestitures.
Outbound Investments
- Teleflex acquired Palette Life Sciences AB in October 2023, an acquisition that contributed to better-than-expected performance, with 2024 revenue guidance for Palette raised to $70-$72 million.
- In July 2025, Teleflex completed the acquisition of substantially all of BIOTRONIK's Vascular Intervention business for €760 million (approximately $826 million). This acquisition expanded Teleflex's interventional portfolio with devices such as drug-coated balloons, stents, and balloon catheters, and was expected to generate approximately €177 million in revenue in the second half of 2025.
Capital Expenditures
- For the 2023 Footprint realignment plan, Teleflex expected to incur $2 million to $3 million in aggregate capital expenditures, mostly in 2024, focusing on relocating manufacturing operations to lower-cost locations.
- By June 2024, the company incurred $1.1 million in pre-tax restructuring related charges under the 2024 Footprint realignment plan, with the majority of associated capital expenditures anticipated by the end of 2025.
- Capital expenditures for the third quarter of 2025 were reported as $29.9 million.
Latest Trefis Analyses
Trade Ideas
Select ideas related to TFX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 10.0% | 10.0% | -8.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 100.66 |
| Mkt Cap | 70.0 |
| Rev LTM | 21,000 |
| Op Inc LTM | 3,538 |
| FCF LTM | 3,018 |
| FCF 3Y Avg | 2,614 |
| CFO LTM | 3,964 |
| CFO 3Y Avg | 3,491 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.4% |
| Rev Chg 3Y Avg | 8.1% |
| Rev Chg Q | 12.3% |
| QoQ Delta Rev Chg LTM | 3.1% |
| Op Mgn LTM | 19.2% |
| Op Mgn 3Y Avg | 18.4% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 20.3% |
| CFO/Rev 3Y Avg | 19.6% |
| FCF/Rev LTM | 16.1% |
| FCF/Rev 3Y Avg | 15.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 70.0 |
| P/S | 3.9 |
| P/EBIT | 24.8 |
| P/E | 28.6 |
| P/CFO | 17.8 |
| Total Yield | 3.3% |
| Dividend Yield | 0.7% |
| FCF Yield 3Y Avg | 3.6% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -5.4% |
| 3M Rtn | -5.9% |
| 6M Rtn | -9.1% |
| 12M Rtn | -2.7% |
| 3Y Rtn | 7.6% |
| 1M Excs Rtn | -4.0% |
| 3M Excs Rtn | -1.7% |
| 6M Excs Rtn | -6.5% |
| 12M Excs Rtn | -27.5% |
| 3Y Excs Rtn | -54.3% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Vascular | 904 | 708 | 684 | 700 | 658 |
| Surgical | 405 | 427 | 393 | 378 | 317 |
| Interventional | 397 | 511 | 445 | 428 | 382 |
| Other | -6 | 292 | 285 | 337 | 367 |
| Anesthesia | 390 | 389 | 380 | 302 | |
| Interventional urology | 320 | 323 | 342 | 290 | |
| Original Equipment and Development Services (OEM) | 326 | 273 | 246 | 220 | |
| Total | 1,700 | 2,974 | 2,791 | 2,810 | 2,537 |
Price Behavior
Price Behavior
| Market Price | $115.04 | |
| Market Cap ($ Bil) | 5.1 | |
| First Trading Date | 02/18/1988 | |
| Distance from 52W High | -15.8% | |
| 50 Days | 200 Days | |
| DMA Price | $110.30 | $117.13 |
| DMA Trend | down | down |
| Distance from DMA | 4.3% | -1.8% |
| 3M | 1YR | |
| Volatility | 44.4% | 39.0% |
| Downside Capture | 0.62 | 0.64 |
| Upside Capture | 104.62 | 64.51 |
| Correlation (SPY) | 26.3% | 37.5% |
TFX Betas & Captures as of 3/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.80 | 0.83 | 0.92 | 0.99 | 0.79 | 0.80 |
| Up Beta | 0.31 | 0.76 | 1.55 | 1.03 | 0.70 | 0.67 |
| Down Beta | 0.31 | 1.15 | 0.09 | 1.20 | 0.84 | 0.86 |
| Up Capture | 43% | 104% | 113% | 80% | 55% | 29% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 9 | 17 | 30 | 59 | 117 | 358 |
| Down Capture | 109% | 35% | 122% | 99% | 104% | 103% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 13 | 25 | 33 | 66 | 134 | 387 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TFX | |
|---|---|---|---|---|
| TFX | -17.8% | 39.1% | -0.41 | - |
| Sector ETF (XLV) | 2.8% | 17.6% | 0.00 | 43.7% |
| Equity (SPY) | 15.3% | 19.0% | 0.64 | 38.4% |
| Gold (GLD) | 49.6% | 28.0% | 1.44 | 5.3% |
| Commodities (DBC) | 15.5% | 17.7% | 0.74 | 3.9% |
| Real Estate (VNQ) | 3.1% | 16.5% | 0.01 | 36.8% |
| Bitcoin (BTCUSD) | -19.0% | 44.0% | -0.35 | 17.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TFX | |
|---|---|---|---|---|
| TFX | -22.1% | 33.7% | -0.67 | - |
| Sector ETF (XLV) | 6.1% | 14.5% | 0.24 | 47.4% |
| Equity (SPY) | 11.7% | 17.0% | 0.53 | 43.2% |
| Gold (GLD) | 21.8% | 17.8% | 1.01 | 10.9% |
| Commodities (DBC) | 11.6% | 18.8% | 0.50 | 5.2% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.09 | 42.8% |
| Bitcoin (BTCUSD) | 3.0% | 56.5% | 0.27 | 16.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TFX | |
|---|---|---|---|---|
| TFX | -2.3% | 31.7% | -0.00 | - |
| Sector ETF (XLV) | 9.9% | 16.5% | 0.49 | 54.8% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 52.6% |
| Gold (GLD) | 14.0% | 15.9% | 0.73 | 7.3% |
| Commodities (DBC) | 8.4% | 17.6% | 0.39 | 13.5% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.21 | 47.8% |
| Bitcoin (BTCUSD) | 65.9% | 66.9% | 1.05 | 13.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/26/2026 | 6.4% | 6.5% | -1.0% |
| 11/6/2025 | -13.0% | -10.6% | -3.7% |
| 7/31/2025 | 4.9% | -1.6% | 11.1% |
| 2/27/2025 | -21.7% | -24.5% | -21.3% |
| 10/31/2024 | -14.5% | -14.2% | -17.9% |
| 8/1/2024 | 6.8% | 2.0% | 10.4% |
| 5/2/2024 | -6.1% | -5.2% | -1.0% |
| 2/22/2024 | -5.3% | -10.4% | -10.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 6 | 9 |
| # Negative | 14 | 15 | 12 |
| Median Positive | 4.9% | 3.7% | 8.8% |
| Median Negative | -5.2% | -6.5% | -11.1% |
| Max Positive | 11.6% | 6.9% | 21.6% |
| Max Negative | -21.7% | -24.5% | -21.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/27/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 07/31/2025 | 10-Q |
| 03/31/2025 | 05/01/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 08/02/2024 | 10-Q |
| 03/31/2024 | 05/03/2024 | 10-Q |
| 12/31/2023 | 02/23/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 10/27/2022 | 10-Q |
| 06/30/2022 | 07/28/2022 | 10-Q |
| 03/31/2022 | 04/28/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 2/26/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 GAAP Revenue Growth | 14.4% | 14.9% | 15.4% | ||||
| 2026 Pro forma adjusted constant currency revenue growth | 4.5% | 5.0% | 5.5% | ||||
| 2026 GAAP EPS | 2.9 | 3.05 | 3.2 | ||||
| 2026 Adjusted diluted EPS | 6.25 | 6.4 | 6.55 | ||||
| 2026 Annual pre-tax savings | 48.00 Mil | 50.00 Mil | 52.00 Mil | ||||
Prior: Q4 2025 Earnings Reported 1/8/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | 3.27 Bil | 3.27 Bil | 3.28 Bil | ||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Randle, Stuart A | Direct | Buy | 8072025 | 115.86 | 1,000 | 115,860 | 874,395 | Form | |
| 2 | Krakauer, Andrew A | Direct | Buy | 8072025 | 115.25 | 1,000 | 115,250 | 828,879 | Form | |
| 3 | Kelly, Liam | Chairman, President & CEO | Direct | Buy | 8072025 | 115.07 | 1,500 | 172,605 | 5,208,907 | Form |
| 4 | Ryu, Jaewon | Direct | Buy | 8072025 | 115.00 | 1,500 | 172,500 | 428,605 | Form | |
| 5 | Haggerty, Gretchen R | Direct | Buy | 8072025 | 114.75 | 500 | 57,375 | 723,499 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.